Main > > >BREAST CANCER. *
Benign FibroAdenoma. Treat.: CryoAbla-
tion System. (I)
Being Used at IL Hospital.
Surgery-Free Technology.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2018. 09.23.
Benign FibroAdenoma. Treat.: CryoAbla-
tion System. (U)
Global Launch Date: 2018. 09.20.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.22.
Companion Diag. Estrogen Receptor-+(ER+)
Liquid Biopsy. CTCs+ctDNA Technology.
USA Launch Date: 2014. 06.03.
(*) Companies; Patents; TradeMarks &
Web-Sites Available on Request.
UpDate: 2018. 06.14.
Companion Diag. Estrogen Receptor-+(ER+)
HER2-. 21 Genes Activity Exam.
Chemotherapy Benefit Prediction.
Recurrence Prediction.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.17.
Companion Diag. Estrogen Receptor-+(ER+)
HER2-. Lymph Node+
EU Launch Date: 2018. 02.06.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.17.
Companion Diag. Estrogen Receptor+(ER+)/
Progesterone Receptor+(PR+)/HER2-/Metas-
tasis less than 3 lymph nodes (pN0/1)
& did not receive preoperative CT.
9 Genes Test.
(*) Company : GenCurix Inc. (KR)
TradeMark: GenesWell BCT.
Web-Site :
www.gencurix.com/engcodingfiles
UpDate: 2018. 06.19.
Companion Diag. FGFR1 Amplified+
Liquid Biopsy. CTCs+ctDNA Technology.
USA Launch Date: 2015. 07.01.
(*) Companies; Patents; TradeMarks &
Web-Sites Available on Request.
UpDate: 2018. 06.17.
Companion Diag. Function Cell Analysis>
>Drug Therapy Match Cancer Biology.
Cell: Live Tumor Cell.
CELx Signaling Function Technology.
(*) Company; Patents & Web-Site Avai-
lable on Request.
UpDate: 2018. 09.29.
Companion Diag. HER2+. FISH DNA Probe Kit II.
EU>CE Marked.
(*) Company : Abbott.
Patent : Expired on 2006. 12.31.
TradeMark: PATHVYSION HER-2 DNA
PROBE KIT II
UpDate: 2018. 06.17.
Companion Diag. HER2+ (U>M)
Now Available
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.17.
Companion Diag. HER2/neu+
Liquid Biopsy. CTCs+ctDNA Technology.
USA Launch Date: 2011. 07.28.
(*) Company; Patents; TradeMarks & Web-
Sites Available on Request.
UpDate: 2018. 06.18.
Companion Diag. Progesterone Receptor+
Liquid Biopsy. CTCs+ctDNA Technology.
USA Launch Date: 2017. 07.14.
(*) Company; Patents; TradeMarks & Web-
Sites Available on Request.
UpDate: 2018. 06.18.
Diag. Artificial Intelligence (AI) Po-
wered for Breast Biopsies.
Company s AI Powered "Algorithm" Compa-
red with "Pathology" Lab Diag.
Deployed at Israel>Maccabi s Pathology Institute.: 2019. 12.04.
(*) Company : Ibex Medical Analytics
Ltd
TradeMark: Second Read
Web-Site : ibex-ai.com/
UpDate: 2019. 12.27.
Diag. Biopsy. 2D/3D X-Ray Imaging.
EU Approval Date: ?
USA Launch Date : 2016. 04.21.
(*) Company : Hologic Inc.
TradeMark: Affirm.
Web-Site : www.affirmpronebiopsy.com
UpDate: 2018. 06.14.
Diag. Biopsy. 2D X-Ray. 3 Steps
(*) Company : Hologic Inc.
TradeMark: Brevera
Web-Site : www.breverabiopsy.com
UpDate: 2018. 06.14.
Diag. Biopsy. 3D X-Ray (U>H)
>Guided
>Vacuum Assisted
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.14.
Diag. Biopsy. 3D X-Ray. (U>K)
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.15.
Diag. Biopsy. Device Platform. (U)
USA FDA 510(k) Clearance: 2018. 06.20.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 08.01.
Diag. Biopsy. Micro Pulse Technology.
Used under UltraSound (US) Guidance
EU CE Mark Date: 2019. 10.29.
UK Launch Date: 2020. 11.19.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.19.
Diag. Biopsy. MRI.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.14.
Diag. Biopsy. MRI. Markers.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.14.
Diag. Biopsy. UltraSound. Vacuum Assisted.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.14.
Diag. Biopsy. X-Ray.
(*) Company; Patents; Product Name &
Web-Site Available on Request.
UpDate: 2018. 06.14.
Diag. BRCA1 & BRCA2 Gene Mutation Test.
(Hereditary)
(*) Company : Myriad Genetics Inc.
Patent : Expired on 2015. 06.07.
TradeMark: BRACAnalysis
Web-Site :
myriad.com/products-
services/hereditary-
cancers/bracanalysis/
UpDate: 2018. 06.18.
Diag. Computer Aided Detection (CAD).
Machine Learning for the Evaluation of Breast Abnormalities.
Software platform, with advanced Analytics and machine learning at its core. Embedded exclusive tools - QI Score™ and Similar Case Database Compare™ - provide similarity assessment to a robust database of abnormalities with clinically documented pathology.
USA Approval Date: 2017. 07.27.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2020. 01.07.
Diag. Imaging. 2D X-Ray. (F)
USA Approval Date: 2017. 12.28.
(*) Company : Planmed OY.
TradeMark: Planmed Clarity
Web-Site :
www.planmed.com/Mammography/Digital-
mammography/Planmed-Clarity-2D/
UpDate: 2018. 06.14.
Diag. Imaging. 2D X-Ray. AI Software.
EU CE Mark Date : ?
USA Approval Date: 2020. 07.27.
(*) Company; Patent; Product Name & Web-
Site Available on Request.
UpDate: 2021. 03.01.
Diag. Imaging. 2D X-Ray. Contrast Enhan-
ced Mammography (CEM).
USA Clearance Date: 2019. 12.19.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2019. 12.23.
Diag. Imaging. 2D/3D X-Ray. PACS.
(*) Company : Infinitt Co. Ltd.
UpDate: 2018. 06.14.
Diag. Imaging. 2D X-Ray. (U)
Better Than Screen FILM Mammography
Mammo.: MammoGraphy (X-Ray)
UK Launch Date : 2003. 04.24.
USA Approval Date: 2002. 10.02.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2018. 06.14.
Diag. Imaging. 2D X-Ray. AI Software.
EU CE Mark Date : 2021. 01.12.
USA Clearance Date: 2020. 07.09.
(*) Company; TradeMark & Web-Site Avai-
lable on Request.
UpDate: 2021. 02.28.
Diag. Imaging. 2D X-Ray. Computer
Aided Detection (CAD). (K)
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.19.
Diag. Imaging. 2D X-Ray. Computer
Aided Detection (CAD). (U>H)
USA Approval Date: 2004. 04.13.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.14.
Diag. Imaging. 2d X-Ray. Computer Aided
Detection. (U>I).
. USA Approval Date: 2013. 01.07>
>On Royal Philips>MicroDose Full-
Field Digital Mammography System
. USA Approval Date: 2013. 06.21>
>On Fujifilm>Aspire HD Digital>
Mammography System
. USA Introduction Year: 2012.
. USA Launch Date: 2016. 04.08>
>On Fujifilm>Aspire Cristalle Full>
Digital Mammography System
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.15.
Diag. Imaging. 2D X-Ray. Computer Aided
Detection (CAD). (U>T)
EU Approval Date: ?
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.15.
Diag. Imaging. 2D X-Ray. Computer Aided
Detection (CAD). Density Assessment SoftWare.
USA Launch Date: 2015. 07.07.
(*) Company : iCAD Inc.
TradeMark: PowerLook Density
Assessment
Web-Site :
www.icadmed.com/powerlook-density-
assessment.html
UpDate: 2018. 06.15.
Diag. Imaging. 2D X-Ray. Cushion.
Radiolucent Breast Cushion.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.14.
Diag. Imaging. 2D X-Ray. WorkStations.
(U>H)
USA Approval Date: 2004. 08.12.
USA Launch Date : 2009. 11.25.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.14.
Diag. Imaging. 2D X-Ray. WorkStations.
(U>T)
Cleared in CA, EU & USA.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.15.
Diag. Imaging. 3D UltraSound. Computer
Aided Detection (CAD).
With Dense Breast Tissue.
USA Approval Date: 2017. 12.22.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.19.
Diag. Imaging. 3D UltraSound. System.
USA 1st 510(k) OK: 2013.
USA 2nd 510(k) OK: 2014. 12.02.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2018. 06.14.
Diag. Imaging. 3D X-Ray. (I)
(*) Company : im3D SPA
Web-Site:
www.i-
m3d.com/en/product/detail/breast-
dts/
UpDate: 2018. 06.14.
Diag. Imaging. 3D X-Ray. (U)
TomoSynthesis+2D Mammography
EU Launch Date : 2008. 09?
USA Approval Date: 2011. 02.11.
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.14.
Diag. Imaging. 3D X-Ray. Computer Aided
Detection (CAD). (U>H).
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2018. 06.14.
Diag. Imaging. 3D X-Ray. Computer Aided
Detection (CAD). (U>I)
CA Approval Date : 2016. 11.28.
EU Approval Date : 2016. 04.
USA Approval Date: 2017. 03.27.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.15.
Diag. Imaging. 3D X-Ray. Cushion.
Radiolucent Breast Cushion.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.14.
Diag. Imaging. 3D X-Ray. Density
Assessment Software.
USA Clearance Date: 2017. 11.24.
(*) Company : Hologic Inc.
TradeMark: Quantra™ 2.2.
UpDate: 2018. 06.14.
Diag. Imaging. 3D X-Ray. Low Dose Ver-
sion.
EU Launch Date : 2011. 11.27.
USA Approval Date: 2013. 05.21.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2018. 06.14.
Diag. Imaging. Positron Emission Tomography (PET). Computer Aided Detection (CAD).
EU Approval Date: ?
USA Launch Date : 2017. 05.22.
(*) Company : OncoVision
Web-Site: oncovision.com/mammi/
UpDate: 2018. 06.14.
Diag. Imaging. Reporting & Tracking
Software.
(*) Company : Ikonopedia Inc.
Web-Site : www.ikonopedia.com/
UpDate: 2018. 06.15.
Diag. Imaging. Reporting & Tracking
Software.
(*) Company : MRS Systems Inc.
TradeMark: Aspen Breast
Web-Site :
mrsys.com/products/aspen-breast
UpDate: 2018. 06.15.
Diag.>Imaging. Single Photon Emission
Computerized Tomography (SPECT). Radio-
Pharma: Technetium Tc 99m Tilmanocept
Injection.
USA Approval Date: 2013.05.01.>
>Guiding Sentinel Lymph Node in Patients
with Breast Cancer; Melanoma
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 03.22.
Diag. Imaging. UltraSound. Automated Whole Breast (AWB).
Why?>Dense Breasts
USA FDA 510k Clearance
(*) Company : SonoCine Inc.
Web-Site : www.sonocine.com
UpDate: 2018. 06.15.
Diag. Metastatic Cancer CTC Pa-
nel.
USA Launch Date: 2017. 11.30.
(*) Company : Epic Sciences Inc.
UpDate: 2018. 06.13.
Diag. Molecular Breast Imaging (MBI).
Scanner. Gamma Camera>>
>Cd Zn Te (CZT) Semiconductor Sensors
>Dense Breasts.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.15.
Diag. NGS BRCA 1/2 In-Vitro Test
Panel.
EU Approval Date: 2017. 07.06.
(*) Company : NGeneBio Co. Ltd.
TradeMark: BRCAaccuTest
Web-Site :
ngenebio.com/products/ngs-cancer-
panel/brcaaccutest/
UpDate: 2018. 06.13.
Diag. Protein Blood Test.
USA Approval Date: ?.
(*) Company; Patent APPs.; TradeMark &
Web-Site Available on Request.
UpDate: 2018. 06.14.
Diag. Total Biochemical Infrared Analysis (TBIA) Blood Test.
EU Approval Date: 2013. 12.
(*) Company; Patent & Web-Site Avai-
lable on Request.
UpDate: 2018. 06.13.
Endoscopy System.
(*) Company : Solos Endoscopy Inc.
TradeMark: MammoView
Web-Site :
solosendoscopy.com/mammoview/
UpDate: 2020. 01.15.
Genetics. Testing Panel. Guide.
Surgical Decisions. Choice:
- Lumpectomy
- Mastectomy
- Salpingo-Oophorectomy
USA Launch Date: 2016. 07.20.
(*) Company : Invitae Corp.
UpDate: 2018. 06.15.
Prognostics. CTCs. Detecting Test.
(Metastatic)
Patent>US Expiration: 2019. 02.12.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.18.
Prognostics. Information on 3 Genetic Variants found on the BRCA1 and BRCA2 Genes.
USA Approval Date: 2018. 03.06.
(*) Company: 23andMe Inc.
UpDate: 2020. 01.20.
Prognostics. Matrix Col XI-α1 Scan.
(Metastatic)
IHC: ImmunoHistoChemical
Used in Hospitals in the USA:
- John Hopkins
- Cedars Mount Sinai in Los Angeles
(*) Company; Patent; TradeMark & Web-
Sites Available on Request.
UpDate: 2018. 06.18.
Prognostics. pro-ENK & pro-NT Blood
Test.
Launch Date: 2017. 03.29.
(*) Company : GeneNews
TradeMark: BreastSentry
Web-Site :
www.genenews.com/breast-cancer.html
UpDate: 2018. 06.15.
Prognostics. Scoring Tool.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.08.
Recurrence. 70-Gene Assay.
USA Approval Date: ?
(*) Company : Agendia NV.
TradeMark: Mammaprint
Web-Site :
www.agendia.com/healthcare-
professionals/breast-
cancer/mammaprint/
UpDate: 2018. 06.15.
Treat.: Abemaciclib Tablets+>
(HR+; HER2-;Metastatic)
+Fulvestrant
>Progressed>Endocrine Therapy
CA Approval Date: 2019. 04.09.
CA Launch Date: 2019. 08.08.
USA Approval Date: 2017. 09.28.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 11.28.
Treat.: Alpelisib Tab.(*)+Fulvestrant.
(HR+/HER2-; METASTATIC; PIK3CA-Mutated)
>Endocrine-based regimen
Companion Diagnostics>
>USA Approval Date: 2019. 12.04.
Kinase Inhibitor
CA Approval Date : 2020. 08.13.
USA Approval Date : 2019. 05.24.
(*) Companies; Patents (*); TradeMarks &
Web-Sites Available on Request.
UpDate: 2020. 10.01.
Treat.: Anastrozole Tablets. Brand.
[HR+; PostMenopausal (PM)]
USA Approval Date: ?
(*) Company (USA): ANI Pharma.
Company (EMEA): Juvise Pharma.
www.juvisepharmaceuticals.com/
Licensor : AstraZeneca.
Patent : Expired on 2009. 12.27.
TradeMark: Arimidex.
Web-Site : www.arimidex.com (USA)
UpDate: 2019. 12.21.
Treat.: AtezolizuMAb+PacliTaxel-Albumin
Particles for Inj. Suspension.
(ER->HER2/neu->PR->METASTATIC>PD-L1-+)
USA Approval Date: 2019. 03.08.
Companion Diagnostic Test>
>Begins Offering Date: 2019. 03.18.
(*) Companies; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2019. 03.19.
Treat.: BevacizuMAb. BioSimilar+
(Metastatic)
+Paclitaxel.
EU Approval Date : 2018. 01.18.
USA Approval Year: 2017.
(*) Company : Amgen.
TradeMark: MVASI™
UpDate: 2019. 11.12.
Treat.: BevacizuMAb. BioSimilar+
(Metastatic)
+Paclitaxel.
EU Approval Date : 2019. 02.19.
(*) Company : Pfizer.
TradeMark: ZIRABEV
UpDate: 2019. 02.20.
Treat.: BrachyTherapy. PostLumpectomy.
(USA>C).
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.17.
Treat.: BrachyTherapy. PostLumpectomy.
(U>H).
USA Approval Date: 2009. 09.01.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.17.
Treat.: BrachyTherapy. PostLumpectomy.
(U>I)
X-Ray Therapy.
AU Approval Date : 2017. 05.01.
CA Approval Date : 2015. 10.19.
CN Approval Date : 2017. 08.30.
EU Approval Date : 2015. 10.19.
USA Approval Date: 2015. 10.19.
(*) Companies; Patents & Web-Site Avai-
lable on Request.
UpDate: 2018. 06.17.
Treat.: Capecitabine Tablets. Brand.
(Metastatic)
>+DoceTaxel after Failure of
Prior Anthracycline-Contg. Therapy
>MonoTherapy in Patients Resistant>
To PacliTaxel & Anthracycline ..
Nucleoside Metabolic Inhibitor.
ProDrug>Converts To 5-F Uracil.
USA Approval Date: 1998. 04.30.
(*) Company : Roche>Genentech.
Patent : Expired on 2011. 01.13.
TradeMark: Xeloda
UpDate: 2018. 06.18.
Treat.: Capecitabine Tablets. Generic.
(Metastatic)
>+DoceTaxel after Failure of
Prior Anthracycline-Contg. Therapy
>MonoTherapy in Patients Resistant>
To PacliTaxel & Anthracycline ..
Nucleoside Metabolic Inhibitor.
ProDrug>Converts To 5-F Uracil.
USA Launch Date: 2019. 04.08.
(*) Company: Armas Pharmaceuticals.
UpDate: 2019. 11.14.
Treat.: DoceTaxel Inj.
(Metastatic)
USA Initial Approval Year: 1996.
(*) Company : sanofi-aventis U.S. LLC
TradeMark: Taxotere.
UpDate: 2018. 06.18.
Treat.: DoceTaxel Inj. Alcohol-Free.
(Metastatic)
USA Approval Date: 2015. 12.28.
USA Launch Date: 2016. 02.02.
(*) Company; Patents; PR Web-Site &
TradeMark Available on Request.
UpDate: 2018. 10.29.
Treat.: DoxoRubicin.HCl NanoParticle Vitamin A Formulation.
RU Approval Date: 2017. 08.08.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2018. 10.01.
Treat.: Eribulin Mesylate Inj. 0.5 mg/ml
(J)
(Metastatic & received other types of anticancer medicines after the cancer has spread)
Halichondrin B Synthetic Analog.
Approved In: AU; CA; EU; JP & USA.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.17.
Treat.: Everolimus Tablets.
(HR+; HER2-; Metastatic)
+Exemestane
EU Approval Date: 2012. 07.30.
USA Approval Date: 2012. 07.20.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.23.
Treat.: Exemestane Tablet. Generic.
USA Launch Date: 2017. 03.13.
(*) Company: Mylan NV.
UpDate: 2018. 06.17.
Treat.: Fulvestrant. Brand.
(HR+; HER2-; Metastatic; PM)
USA Approval Date: 2017. 08.28.
(*) Company : AstraZeneca
Patent : Expired on 2007. 12.
TradeMark: Faslodex
Web-Site : www.faslodex.com
UpDate: 2018. 06.18.
Treat.: Fulvestrant. Generic.
(HR+; HER2-; METASTATIC; PM)
USA Launch Date: 2019. 10.07.
(*) Company: Fresenius Kabi.
UpDate: 2019. 12.02.
Treat.: Fulvestrant. Generic.
(HR+; HER2-; METASTATIC; PM)
USA Launch Date: 2019. 09.17.
(*) Company: Mylan.
UpDate: 2020. 01.02.
Treat.: Fulvestrant. Brand.
[(HR+; PostMenopausal (PM)]
(*) Company : AstraZeneca.
Patent : Expired.
TradeMark: Faslodex.
Web-Site : www.faslodex.com
UpDate: 2018. 06.18.
Treat.: Fulvestrant. Generic.
[(HR+; PostMenopausal (PM)]
USA Launch Date: 2019. 09.17.
(*) Company : Mylan.
UpDate: 2020. 01.02.
Treat.: Fulvestrant+Abemaciclib. Brand.
(HR+; HER2-; Metastatic)
USA Approval Date: 2017. 11.15.
(*) Company : AstraZeneca.
TradeMark: Faslodex
Web-Site : www.faslodex.com
UpDate: 2018. 06.18.
Treat.: Fulvestrant+Abemaciclib. Generi.
(HR+; HER2-; Metastatic)
USA Launch Date: 2019. 09.17.
(*) Company : Mylan.
UpDate: 2020. 01.02.
Treat.: Fulvestrant+Palbociclib. Brand.
(HR+; HER2-; Metastatic)
USA Approval Date: 2016. 03.02.
(*) Company : AstraZeneca.
TradeMark: Faslodex
Web-Site : www.faslodex.com
UpDate: 2018. 06.18.
Treat.: Fulvestrant+Palbociclib. Generi.
(HR+; HER2-; Metastatic)
USA Launch Date: 2019. 09.17.
(*) Company : Mylan.
UpDate: 2020. 01.02.
Treat.: Gemcitabine.HCl Inj.+Paclitaxel.
(Metastatic after failure of prior anthracycline-containing adjuvant CT)
USA Initial Approval Year: 1996.
(*) Company : Eli Lilly.
Patent : Expired
TradeMark: Gemzar
Web-Site :
pi.lilly.com/us/gemzar.pdf
UpDate: 2018. 06.17.
Treat.: Goserelin Acetate Implant. Brand
(HR+; Metastatic).
(*) Company : TerSera Therapeutics LLC
Patent : Expired on 1999. 04.22.
TradeMark: Zoladex
Web-Site :
aboutzoladex.com/breast-cancer.html
UpDate: 2018. 06.18.
Treat.: Goserelin Acetate Implant. Gene-
ric.
(HR+; Metastatic).
EU Launch Date: 2016. 04.05.
(*) Company : Alvogen.
TradeMark: Reseligo.
UpDate: 2018. 06.18.
Treat.: Ixabepilone Epothilone for Inj.
for IV Infusion.
(Metastatic, when certain other medicines have not worked or no longer work. Used alone or with capecitabine).
USA Approval Date: ?
(*) Company; Patents; TradeMark & WEb-
Site Available on Request.
UpDate: 2018. 06.17.
Treat.: Lapatinib 250 mg Tab.+>
(Metastatic; HER2+)
+Capecitabine
>Who Have Received Prior Therapy>
>>Anthracycline; Taxane; TrastuzuMAb
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.18.
Treat.: Lapatinib 250 mg Tab.+>
(Metastatic; HER2+; HR+; PM)
+Letrozole
>Hormonal Therapy is Indicated
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.18.
Treat.: Letrozole Tablets. Brand.
[HR+; PostMenopausal (PM)]
USA Approval Year: 2001.
(*) Company : Novartis.
Patent : Expired.
TradeMark: Femara.
Web-Site : www.femara.com
UpDate: 2018. 06.18.
Treat.: Lumpectomy.
Margin Control. Digital Microscopy Scanner (Version 2) for ultra-fast Confocal Imaging of fresh Excision.
EU Approval Date: 2018. 10.29.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 03.11.
Treat.: Lumpectomy.
Radar Localization.
Uses Radar for a Zero-Radiation and Wire-Free solution designed to aid surgeons in locating target tissue during a Lumpectomy to ±1mm of accuracy
Instead of wires, a small Reflector the size of a grain of rice is placed into the breast prior to the day of surgery.
EU Approval Date : 2020. 02.20.
USA Approval Date: 2017. 11.13.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 02.23.
Treat.: Lumpectomy.
Technology: RadioFrequency Spectroscopy.
USA Approval Date: 2015. 01.05.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.17.
Treat.: Lumpectomy. Localization-Free
Procedure.
Soft Tissue Marker+Surgical Navigation
System provide Alternative for Painful and Costly Localization Procedures.
USA Clearance Date: 2019. 04.11.
(*) Company; Patents; TradeMarks & Web-
Site Available on Request.
UpDate: 2019. 11.29.
Treat.: Lumpectomy. MRI System.
Intra-Operative Margin Imaging System.
AU Approval Date: 2018. 03.19.
EU Approval Date: 2014. 09.23.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 11.27.
Treat.: Lumpectomy. Uses.
3-D Tomosynthesis >Intraoperative>
>breast specimen imaging.
(*) Company : Kub Technologies.
TradeMark: Mozart.
Web-Site : kubtec.com/mozart/
UpDate: 2018. 06.17.
Treat.: MargetuxiMAb Inj. IV Use.
(HER2+; METASTATIC)
USA Approval Date: 2020. 12.16.
(*) Company; TradeMark & Web-Site Avai-
lable on Request.
UpDate: 2021. 02.18.
Treat.: Neratinib Maleate Tablets.
(Adjuvant; HER2+).
Tyrosine Kinase Inhibitor.
AR Approval Date : 2019. 09.04.
EU Approval Date : 2018. 09.04.
MY Approval Date: 2020. 07.16.
USA Approval Date: 2017. 07.17.
USA Launch Date : 2017. 07.31.
(*) Company; Patents; TradeMark & Web-
Site Available on Request
UpDate: 2021. 02.22.
Treat.: Neratinib Maleate Tab.>
>Adjuvant TrastuzuMAb Therapy.
AR Approval Date: ?
CN Approval Date : 2020. 05.07.
EU Approval Date : 2018. 09.04.
HK Approval Date : 2019.
USA Approval Date: 2017. 07.17.
USA Launch Date : 2017. 07.31.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2020. 05.21.
Treat.: Neratinib Maleate+Capecitabine.>
(HER2+; METASTATIC)
>2 Prior Anti-HER2-based Regimens.
USA Approval Date: 2020. 02.26.
(*) Company; Patents; TradeMarks & Web-
Site Available on Request.
UpDate: 2020. 03.03.
Treat.: Olaparib Tablets.>
(gBRCA-; HER2-; Metastatic)
>Mutated>Previously Treat Hormonal >>Therapy>if HR+
>Mutated>Previously Treat with CT
Companion Diagnostics> ..
JP Approval Date: 2018. 07.02.
USA Approval Date: 2018. 01.12.
(*) Company; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2018. 07.03.
Treat.: PacliTaxel-Albumin Bound Particles for Inj Suspension. Brand.
(Metastatic)
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.18.
Treat.: PacliTaxel-Albumin Bound Particles for Inj Suspension. Generic.
(Metastatic)
(*) Company : Cipla.
TradeMark: Paclitax.
Web-Site :
ciplamed.com/content/paclitax-nab-
injection
UpDate: 2018. 06.18.
Treat.: Palbociclib Capsules+
(HR+; HER2-; Metastatic)
+Aromatase Inhibitor (AI)
+Letrozole (L)
(AI) USA Approval Date: 2017. 04.03.
(AI) USA Approval Date: 2019. 04.05.
for Men
(L) USA Approval Date: 2015. 02.03.
Patent Expiration Date: 2027. 03.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.22.
Treat.: PertuzuMAb+TrasruzuMAb+Docetaxel
IV Inj. (150 minutes)
(Adjuvant; HER2+)
CA Approval Date: 2021. 03.16.
USA Approval Date: 2017. 12.20.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 03.17.
Treat.: PertuzuMAb+TrastuzuMAb+Hyaluro- nidase+Docetaxel SubCutaneous Inj.
(5 minutes)
(Adjuvant; HER2+)
EU CE Mark Date : 2020. 12.23.
USA Approval Date: 2020. 06.29.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.24.
Treat.: RadioTherapy. Positioning. (U>O)
EU Approval Date : 2009. 02.26.
USA Approval Date: 2009. 03.12.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 06.17.
Treat.: RadioTherapy. Positioning.
Launch Date: 2017. 09.23.
(*) Company : Qfix Systems LLC.
TradeMark: kVue.
UpDate: 2018. 06.17.
Treat.: RadioTherapy. PostLumpectomy.
Stereotactic RT System.
EU Clearance: 2019. 04.25.
USA Clearance: 2018. 01.09.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2020. 01.13.
Treat.: Ribociclib+
(HR+; HER2-; Metastatic)
+Letrozole (Aromatase Inhibitor)
CDK4/6 Inhibitor
CA Approval Date : 2020. 04.16.
EU Approval Date : 2017. 08.24.
USA Approval Date: 2017. 03.13.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 04.17.
Treat.: SacituzuMAb Govitecan hziy Inj.
for IV Use.>
(ER-; HER2-; PR-; METASTATIC)
>Received > 2 Prior THerapies.
Trop 2 AntiBody/Topoisomerase Inhibitor
Conjugate.
USA Approval Date: 2020. 04.22.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 04.23.
Treat.: Sulforaphane+Cyclodextrin Com-
plex. (U)
(ER+ METastatic PM)
IUPAC Name: 1-Isothiocyanato-4-
methylsulfinylbutane
Status: Phase II
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 08.19.
Treat.: Surgery. Lesion Localization U
Wireless RFID System.
USA FDA 510(k) Clearance: 2017. 04.28.
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 05.12.
Treat.: Surgery. Marker> (U)
>Magnetic Detector.
>Magnetic Seed Marker>>
>>EU Approval Date : 2017. 09.13.
>>USA Approval Date: 2016. 04.04.
(*) Companies; Patents; TradeMarks &
Web-Sites Available on Request.
UpDate: 2018. 06.17.
Treat.: Surgery. Specimen. Computed
Tomography Imaging.
Designed to improve intraoperative specimen margin assessment.
USA FDA 510(k) Clearance: 2018. 05.10.
(*) Company : Faxitron Bioptics LLC.
TradeMark: VisionCT.
Web-Site :
www.faxitron.com/product/visionct/
UpDate: 2018. 05.12.
Treat.: Talazoparib.
[METASTATIC; HER2-; Germline BRCA-Muta-ted (gBRCAm)].
Companion Diagnostics>
>USA Approval Date: 2018. 10.16.
EU Approval Date : 2019. 06.21.
USA Approval Date : 2018. 10.16.
(*) Companies; Patents; TradeMarks &
Web-Sites Available on Request.
UpDate: 2020. 01.08.
Treat.: Toremifene Citrate Tablets 60
mg.
[Estrogen Receptor+(ER+); Metastatic;
PostMenopausal (PM)]
(*) Company : Kyowa Kirin Inc.
Patent : Expired on 2009. 09.29.
TradeMark: Fareston.
Web-Site : www.fareston.com/
UpDate: 2018. 06.17.
Treat.: TrastuzuMAb Inj.IV. BioSimilar.
(Metastatic: HER2+)
USA Launch Date: 2019. 07.18.
(*) Company : Amgen.
TradeMark: KANJINTI
UpDate: 2019. 11.12.
Treat.: TrastuzuMAb Inj.IV. BioSimilar.
(Metastatic; HER2+)
EU Approval Date : 2018. 02.14.
KR Launch Year : 2017.
USA Approval Date: 2018. 12.14.
USA Launch Date : 2020. 03.16.
(*) Companies : Celltrion Inc.
Teva Pharma.
TradeMark: Herzuma
UpDate: 2020. 03.17.
Treat.: TrastuzuMAb Inj.IV. BioSimilar.
(Metastatic; HER2+)
USA Launch Date: 2019. 12.02.
(*) Companies : Mylan NV & BioCon Ltd.
TradeMark : Ogivri.
UpDate: 2020. 01.02.
Treat.: TrastuzuMAb Inj.IV. BioSimilar.
(Metastatic; HER2+)
USA Approval Date: 2019. 03.11.
(*) Company : Pfizer.
TradeMark: TRAZIMERA.
UpDate: 2019. 03.13.
Treat.: TrastuzuMAb Inj.IV. BioSimilar.
(Metastatic; HER2+)
EU Approval Date : 2017. 11.20.
USA Approval Date: 2019. 01.21.
USA Launch Date: 2020. 04.15.
(*) Company : Merck (USA)
Company : Samsung Bioepis Co. Ltd
TradeMark: ONTRUZANT
UpDate: 2020. 04.16.
Treat.: TrastuzuMAb Inj.IV. BioSimilar.
(Metastatic; HER2+)
USA Approval Date: 2017. 12.01.
(*) Company : Mylan.
TradeMark: Ogivri.
UpDate: 2018. 06.18.
Treat.: TrastuzuMAb Inj.IV. BioSimilar.
(Metastatic; HER2+)
EU Approval Date: 2018. 07.31.
(*) Company : Pfizer.
TradeMark: TRAZIMERA
UpDate: 2018. 08.01.
Treat.: TrastuzuMAb Inj.IV. Brand.
(Metastatic; HER2+)
Approved Indications>
>>Alone>treatment of HER2-positive
breast cancer in patients who have
received one or more chemotherapy
courses for metastatic disease
>>+PacliTaxel>first line treatment of
Human Epidermal growth factor Receptor
2-positive (HER2+) metastatic breast
cancer
(*) Company : Genentech.
Patent : Expired on 2014. 08.05.
TradeMark: Herceptin
Web-Site : www.herceptin.com
UpDate: 2018. 06.18.
Treat.: TrastuzuMAb DeruxTecan [AntiBody
Drug Conjugate (ADC)] Inj.>
(Metastatic; HER2+)
>Received >2 Anti-HER2-based Regimens
in the Metastatic Setting.
DeruxTecan: TopoIsomerase I Inhibitor.
EU Approval Date: 2021. 01.20.
JP Approval Date: 2020. 03.25.
USA Approval Date: 2019. 12.20.
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.10.
Treat.: TrastuzuMAb Emtansine [AntiBody
Drug Conjugate (ADC)] Inj.>
(Early Breast Cancer; HER2+).
>Adjuvant Treatment (After Surgery) of
People With Residual Invasive Disease
After Neoadjuvant Treatment (Before
Surgery) including Taxane & Trastuzu
MAb.
USA Approval Date: 2019. 05.03.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.02.
Treat.: TrastuzuMAb Emtansine {AntiBody
Drug Conjugate (ADC)] Inj.>
(Metastatic; HER2+)
>Received TrastuzuMAb & Taxane.
EU Approval Date : 2013. 11.
JP Approval Date : 2013. 09.
USA Approval Date: 2013. 03.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.02.
Treat.: Triptorelin. (DecaPeptide)
(adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, for women at high-risk of breast cancer recurrence.)
UK Approval Date: 2017. 03.13.
(*) Company : Ipsen.
TradeMark: Decapeptyl
UpDate: 2018. 06.17.
Treat.: Tucatinib Tablets>+
(HER2+; METASTATIC)
Tyrosine Kinase Inhibitor.
+Capecitabine+TrastuzuMAb
>UnResectable; Advanced.
AU Approval Date: 2020. 08.12.
CA Approval Date: ?
CH Approval Date: 2020. 05.12.
EU Approval Date: 2021. 02.12.
SG Approval Date: ?
USA Approval Date: 2020. 04.17.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.26.
>BREAST CANCER. *'s products
This section has no products